Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
VERV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.31 - $13.63
Previous CloseN/A
Volume257.30K
Average Volume (3M)1.29M
Market Cap
$492.82M
Enterprise Value-$59.04M
Total Cash (Recent Filing)$172.56M
Total Debt (Recent Filing)$69.98M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
May 07, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.35
Shares Outstanding88,795,770
10 Day Avg. Volume1,157,080
30 Day Avg. Volume1,291,429
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.24
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.83
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$21.43Price Target Upside286.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
CollaborationsLilly obtained opt-in rights to VERVE-102, allowing for a 50/50 cost/profit sharing of its commercialization in the US market, in exchange for funding 33% of worldwide development expenses.
Financial StabilityVERV ended with a strong cash position, providing financial stability into mid-2027.
Safety ProfileVERVE-102 remains well-tolerated with no clinically significant lab abnormalities in the ongoing Phase 1b Heart-2 study for patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.
Bears Say
Adverse EventsA sixth patient in the 0.45mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum ALT and a Grade 3 serious adverse event.
Partnership TerminationVertex terminated the research collaboration for an in vivo gene-editing program for liver disease due to changing priorities.
---
Ownership Overview
15.35% Insiders
12.27% Mutual Funds
44.79% Other Institutional Investors
15.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $4.30 and its highest was $13.63 in the past 12 months.
What is Verve Therapeutics’s market cap?
Verve Therapeutics’s market cap is $492.82M.
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.675 by $0.095.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -0.65.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 88,795,770 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.675. Following the earnings report the stock price went down -1.743%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Currently, no hedge funds are holding shares in VERV
---
Verve Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.43 (286.13% Upside)
$21.43 (286.13% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 69.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.98%
12-Months-Change
Fundamentals
Return on Equity
-36.36%
Trailing 12-Months
Asset Growth
-13.99%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics (VERV) is a biotechnology company focused on developing transformative therapies for patients with cardiovascular diseases. The company operates within the life sciences sector, specializing in gene editing technologies. Verve's core products are designed to provide effective, long-term treatment options for cardiovascular conditions by addressing the underlying genetic causes of these diseases.
---
VERV Stock 12 Month Forecast
Average Price Target
$21.43
▲(286.13% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering VERV
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-36.14%
reiterated a buy rating 26 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -36.14% per trade.
---